Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009
Date:7/14/2009

stors. With our clinical programs on track to generate additional data, and contract revenues from Avid and our DTRA program continuing to increase, we anticipate that FY 2010 could be a very positive year for Peregrine."

The company's Annual Report on Form 10-K will be filed later today and will be available at the SEC's website at www.sec.org, or through the investor portion of Peregrine's website at www.peregrineinc.com.

Operating Highlights Since the Start of Fiscal Year 2009

Bavituximab Anti-Cancer Program

Peregrine reported progress in all four ongoing trials in its bavituximab cancer program, including its three Phase II trials:

  • Completed enrollment of the planned 46 patients in a Phase II trial evaluating bavituximab in combination with docetaxel in advanced breast cancer patients. As reported in an oral presentation at the 2009 ASCO Annual Meeting, 10 of 14, or 71% of evaluable patients in the initial cohort demonstrated an objective tumor response according to RECIST criteria. These data exceeded the pre-specified endpoint needed to expand the trial and compare favorably with historical data with chemotherapy alone. Recent analysis shows the median progression free survival of patients enrolled in the first part of the study was 7.4 months, a promising early result. Patient dosing and follow-up in this trial are continuing.
  • Reported that in a Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients, nine of 14, or 64% of evaluable patients in the initial cohort achieved an objective tumor response according to RECIST criteria. These data exceeded the pre-specified endpoint needed to expand the trial. Patient enrollment and dosing are underway in the
    '/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... last time you experienced worrisome medical symptoms, did ... health-care professional? If so, you,re not alone. Consumers ... peer support groups to gather anecdotal information and ... and trustworthy sources. New research to be presented ... studies the characteristics of consumers who use the ...
(Date:8/27/2014)... August 27, 2014 Will Holbrook, CP ... Will has over 15 years of experience in ... in Rome, Georgia with a Bachelor of Science degree ... chemistry. He received his graduate degree in prosthetics ... excited to have Will join us at Fourroux,” says ...
(Date:8/27/2014)... -- In a new study done from the heights ... pressure steadily increases if you ascend to great heights. ... to treat high blood pressure was ineffective once climbers ... online Aug. 27 in the European Heart Journal ... at sea level who have sleep apnea, in which ...
(Date:8/27/2014)... NJ (PRWEB) August 27, 2014 ... enhancement and protection services for hospitals, is pleased to ... Inc. 5000 List of America’s Fastest-Growing Companies. The list ... of the economy—America’s independent entrepreneurs. , "It's been ... honored to be included in this year's Inc. 5000 ...
(Date:8/27/2014)... 2014 The American Brain Tumor ... the 2014-2016 Basic Research Fellowships and 2014-2015 Discovery Grant ... ABTA is seeding the field with talented, bright young ... of the causes, effects, diagnosis and treatment of brain ... committee based on the potential to advance the understanding ...
Breaking Medicine News(10 mins):Health News:Educated consumers more likely to use potentially unreliable online healthcare information 2Health News:Everest Study Finds High Altitude Affects Blood Pressure 2Health News:BESLER Consulting Among America’s Fastest Growing Private Companies 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 3
... the tourist resort city of Livingstone were tested for bird ... backyards'. // ,Simon Miti, the permanent secretary at ... thorough investigation of the outbreak'. ,The number of ... residents who cooked and ate the dead chickens have been ...
... is found to enhance educational achievements and combat other behavioral ... that it has a positive effect on the kids suffering ... responded better to Omega 3 fish oils than to the ... found that fish oil is very essential for the kids. ...
... the killer of Lin and Megan Russell has petitioned the High ... public since it would be misused by the press. ... committed a decade ago. Stone's lawyer, Richard Clayton QC said that ... be seriously misused by the tabloid press. ,Mr Clayton ...
... Delhi Police summoned three doctors of the Indraprastha Apollo ... //on the condition of Rahul Mahajan, who was admitted ... overdose. ,"We have summoned the doctors and ... of police, heading the probe against the hospital. ...
... introduce a common school system in the country, educationists ... the primary education //system and remove disparities among students. ... school system in the country so that all students ... students," said Madhu Prasad, educationist and a professor in ...
... According to a new study published in the Journal ... epileptic seizures by inducing rhythmical //electrical activity in the ... the hippocampus. The researchers found that, by imposing a ... reduce epileptic seizures by 86-97%. ,The study ...
Cached Medicine News:Health News:Police Summoned Apollo Doctors in Rahul Mahajan’s Cas 2Health News:Brain Septum Could Help In reducing Epileptic Seizures 2Health News:Brain Septum Could Help In reducing Epileptic Seizures 3
(Date:8/27/2014)... NINGBO, China , Aug. 27, 2014  Amerigen ... Ltd, ("Menovo") today announced they had entered into a ... targeting the United States market. ... will jointly develop products for Amerigen to commercialize in ... be responsible for manufacturing API and finished product whereas ...
(Date:8/27/2014)... , Aug. 27, 2014 /PRNewswire-iReach/ -- "Fatty Liver ... on the Fatty Liver Disease clinical trial scenario. This ... clinical trials on Fatty Liver Disease . It ... recruitment status as per the site of trial conduction ... of disease clinical trials by their phase, trial status, ...
(Date:8/27/2014)... -- After the February 2014 launch of their new ... medical practices and management companies, Prime Clinical is reporting ... "The feedback has been great," says Director of ... of demos and new sign-ups is a reflection of ... of software features." Prime Clinical developed ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Limited and the Ningbo Menovo Pharmaceutical Co., Ltd, today announced they had entered into a collaboration agreement regarding the development of generic pharmaceuticals, primarily targeting the United States market 2Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 2Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 3Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 4Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 5Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 2Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 3
... 18 Oramed,Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( ... announced today that its abstract, entitled "Open,Label ... and,Pharmacodynamics (PD) of Five Oral Insulin Formulations ... at the upcoming 44th Annual,Meeting of the ...
... Research Relationships and Proven, Track Record ... SANTA CLARA, Calif., Aug. 18 NewCardio, Inc.,(OTC ... company, today,announced that Vincent W. Renz has joined ... Company,s commercialization effort, to include,business development, client services, ...
Cached Medicine Technology:Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome) 2Vincent W. Renz Joins NewCardio as President 2Vincent W. Renz Joins NewCardio as President 3Vincent W. Renz Joins NewCardio as President 4
... assembly. Superb Bi-Polar range of ... Superior pull-out and lever-out strength. ... 44, 48, 52, 56, 60 ... component for all shells. Increased ...
... index. A/P and lateral fins with holes ... medial hole, humeral / glenoid diametral curvature ... textured proximal surface to provide enhanced proximal ... cement, six stem sizes, fifteen head sizes ...
...
...
Medicine Products: